Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

Rhea-AI Summary

Biodesix (NASDAQ: BDSX) has partnered with the Association of Pulmonary Advanced Practice Providers (APAPP) to launch the first CME-accredited educational programs focused on diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs. The collaboration aims to educate healthcare providers about innovative lung nodule risk assessment tools like the Nodify Lung blood-based tests and cancer treatment decision support testing such as IQLung blood-based tests. The initiative addresses the critical need for improved lung cancer detection, as lung cancer remains the deadliest cancer type, with 1 in 18 Americans expected to receive a diagnosis in their lifetime. The partnership focuses on empowering providers in both rural and metropolitan settings to better serve diverse patient populations despite resource limitations.

Positive

• Partnership with APAPP expands market reach and adoption potential for Biodesix's diagnostic tests
• Educational program could lead to increased utilization of Nodify Lung and IQLung blood-based tests
• Strategic positioning in the lung cancer diagnostic market through first-of-its-kind CME program

Negative

• None.

Insights

Healthcare Industry Analyst

Biodesix's APAPP partnership should drive adoption of their lung cancer diagnostics through targeted medical education, potentially expanding market reach.

Biodesix's new partnership with the Association of Pulmonary Advanced Practice Providers (APAPP) represents a strategic market development initiative that could accelerate adoption of the company's diagnostic portfolio. This collaboration targets Advanced Practice Providers (APPs) - nurse practitioners and physician assistants who serve as critical decision-makers in pulmonary care settings, particularly in underserved areas.

The educational programs will specifically promote awareness of Biodesix's two key product lines: the Nodify Lung blood-based tests for nodule risk assessment and the IQLung tests for cancer treatment decision support. This approach addresses a significant market opportunity, as lung cancer remains the deadliest cancer type in the US with approximately 1 in 18 Americans receiving a diagnosis in their lifetime.

From a commercial perspective, this partnership cleverly navigates the complex healthcare adoption curve by directly educating frontline providers who influence testing decisions. APPs are particularly valuable targets as they often manage large patient populations in diverse settings with limited resources - precisely where efficient diagnostic tools provide the most value.

This represents the first CME-accredited course specifically for APPs on diagnostic biomarkers in lung cancer programs, giving Biodesix a potential first-mover advantage in capturing mindshare among this provider group. While not announcing immediate revenue impact, this education-based market development approach could drive sustained long-term adoption of Biodesix's diagnostic products across a broader range of clinical settings.

Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs

LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer.

In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung^® blood-based tests, or cancer treatment decision support testing, such as the IQLung^® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined.

As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources.

“We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,” said Scott Hutton, CEO of Biodesix. “Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.”

“APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,” said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. “An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients peace of mind. APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.”

About APAPP

APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine.

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung^® Nodule Risk Assessment and IQLung^® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Contacts:

APAPP:
Corinne Young, MSN, FNP, FCCP
President & Founder, APAPP
corinne@pulmapp.com
(719) 425-7040

Biodesix:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com 
(720) 925-9285

FAQ

What is the purpose of Biodesix's partnership with APAPP?

The partnership aims to provide CME-accredited educational programs for Advanced Practice Providers about diagnostic biomarkers in lung nodule and lung cancer patient programs, focusing on tools like Nodify Lung and IQLung blood-based tests.

What diagnostic tests does Biodesix (BDSX) offer for lung cancer?

Biodesix offers the Nodify Lung blood-based tests for lung nodule risk assessment and IQLung blood-based tests for cancer treatment decision support.

How common is lung cancer according to Biodesix's press release?

According to the press release, 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime, and it is the deadliest of all cancers, causing nearly as many deaths as breast, prostate, and colon cancers combined.

Who will benefit from the BDSX and APAPP educational program?

The program will benefit healthcare providers practicing in diverse care settings, both rural and metropolitan, who manage large diverse patient populations with minimal resources.

What is the significance of this educational program for Biodesix?

This is the nation's first CME-accredited course for Advanced Practice Providers focused on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer programs, positioning Biodesix as a leader in the field.